Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Anti-CD3/anti-CD19 bispecific T-cell engager, EX102 |
Target |
Action modulators, stimulants |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Discovery | China | 04 Feb 2021 |